Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II).
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Cardiovascular Diseases
/ diagnosis
Coronavirus Infections
/ diagnosis
Diabetes Mellitus
/ diagnosis
Female
Follow-Up Studies
Humans
Male
Metabolic Diseases
/ diagnosis
Middle Aged
Multimorbidity
/ trends
Pandemics
Pneumonia, Viral
/ diagnosis
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2
COPD
Covid-19
Diabetes
Hypertension
SARS-CoV-2
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
09
07
2020
accepted:
23
09
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Cardiometabolic disorders may worsen Covid-19 outcomes. We investigated features and Covid-19 outcomes for patients with or without diabetes, and with or without cardiometabolic multimorbidity. We collected and compared data retrospectively from patients hospitalized for Covid-19 with and without diabetes, and with and without cardiometabolic multimorbidity (defined as ≥ two of three risk factors of diabetes, hypertension or dyslipidaemia). Multivariate logistic regression was used to assess the risk of the primary composite outcome (any of mechanical ventilation, admission to an intensive care unit [ICU] or death) in patients with diabetes and in those with cardiometabolic multimorbidity, adjusting for confounders. Of 354 patients enrolled, those with diabetes (n = 81), compared with those without diabetes (n = 273), had characteristics associated with the primary composite outcome that included older age, higher prevalence of hypertension and chronic obstructive pulmonary disease (COPD), higher levels of inflammatory markers and a lower PaO2/FIO2 ratio. The risk of the primary composite outcome in the 277 patients who completed the study as of May 15 Patients with diabetes hospitalized for Covid-19 present with high-risk features. They are at increased risk of adverse outcomes, likely because diabetes clusters with other cardiometabolic conditions.
Sections du résumé
BACKGROUND
Cardiometabolic disorders may worsen Covid-19 outcomes. We investigated features and Covid-19 outcomes for patients with or without diabetes, and with or without cardiometabolic multimorbidity.
METHODS
We collected and compared data retrospectively from patients hospitalized for Covid-19 with and without diabetes, and with and without cardiometabolic multimorbidity (defined as ≥ two of three risk factors of diabetes, hypertension or dyslipidaemia). Multivariate logistic regression was used to assess the risk of the primary composite outcome (any of mechanical ventilation, admission to an intensive care unit [ICU] or death) in patients with diabetes and in those with cardiometabolic multimorbidity, adjusting for confounders.
RESULTS
Of 354 patients enrolled, those with diabetes (n = 81), compared with those without diabetes (n = 273), had characteristics associated with the primary composite outcome that included older age, higher prevalence of hypertension and chronic obstructive pulmonary disease (COPD), higher levels of inflammatory markers and a lower PaO2/FIO2 ratio. The risk of the primary composite outcome in the 277 patients who completed the study as of May 15
CONCLUSIONS
Patients with diabetes hospitalized for Covid-19 present with high-risk features. They are at increased risk of adverse outcomes, likely because diabetes clusters with other cardiometabolic conditions.
Identifiants
pubmed: 33004045
doi: 10.1186/s12933-020-01140-2
pii: 10.1186/s12933-020-01140-2
pmc: PMC7528157
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Subventions
Organisme : European Foundation for the Study of Diabetes
ID : MS 2017_2
Pays : International
Investigateurs
Camilla Ajassa
(C)
Rugova Alban
(R)
Francesco Alessandri
(F)
Federica Alessi
(F)
Raissa Aronica
(R)
Valeria Belvisi
(V)
Raffaella Buzzetti
(R)
Matteo Candy
(M)
Alessandra Caputi
(A)
Anna Carrara
(A)
Elena Casali
(E)
Eugenio Nelson Cavallari
(EN)
Giancarlo Ceccarelli
(G)
Luigi Celani
(L)
Maria Rosa Ciardi
(MR)
Lucia Coraggio
(L)
Ambrogio Curtolo
(A)
Claudia D'Agostino
(C)
Gabriella D'Ettorre
(G)
Luca D'Onofrio
(L)
Francesca De Giorgi
(F)
Gabriella De Girolamo
(G)
Valeria Filippi
(V)
Lucio Gnessi
(L)
Cecilia Luordi
(C)
Ernesto Maddaloni
(E)
Claudio Maria Mastroianni
(CM)
Ivano Mezzaroma
(I)
Carmen Mignogna
(C)
Chiara Moretti
(C)
Francesco Pugliese
(F)
Gregorio Recchia
(G)
Marco Ridolfi
(M)
Francesco Eugenio Romani
(FE)
Gianluca Russo
(G)
Franco Ruberto
(F)
Giulia Savelloni
(G)
Guido Siccardi
(G)
Antonio Siena
(A)
Sara Sterpetti
(S)
Serena Valeri
(S)
Mauro Vera
(M)
Lorenzo Volpicelli
(L)
Mikiko Watanabe
(M)
Massimo Aiuti
(M)
Giuseppe Campagna
(G)
Cosmo Del Borgo
(C)
Laura Fondaco
(L)
Blerta Kertusha
(B)
Frida Leonetti
(F)
Gaetano Leto
(G)
Miriam Lichtner
(M)
Raffaella Marocco
(R)
Renato Masala
(R)
Paola Zuccalà
(P)
Felice Eugenio Agrò
(FE)
Giulia Nonnis
(G)
Giuseppe Pascarella
(G)
Paolo Pozzilli
(P)
Alessandra Rigoli
(A)
Alessandro Strumia
(A)
Daniela Alampi
(D)
Monica Rocco
(M)
Références
Diabetes Metab Res Rev. 2020 Apr 26;:e3330
pubmed: 32336007
BMJ Open. 2019 Mar 3;9(3):e024476
pubmed: 30833320
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Am Heart Assoc. 2020 Sep;9(17):e016948
pubmed: 32633594
Metabolism. 2020 Sep;110:154317
pubmed: 32673651
Diabetologia. 2020 Nov;63(11):2486-2487
pubmed: 32632527
Cardiovasc Diabetol. 2019 Jan 19;18(1):9
pubmed: 30660185
Intensive Care Med. 2020 Jun;46(6):1105-1108
pubmed: 32347323
Diabetes Metab Res Rev. 2020 Mar 31;:e33213321
pubmed: 32233018
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
Diabetes Metab Res Rev. 2016 Feb;32(2):169-75
pubmed: 26484614
Nat Rev Cardiol. 2019 Feb;16(2):113-130
pubmed: 30250166
Lancet. 2009 Oct 24;374(9699):1421-2
pubmed: 19854371
Diabetes Res Clin Pract. 2020 Sep 21;:108454
pubmed: 32971157
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Metabolism. 2020 Jul;108:154244
pubmed: 32320741
BMC Med. 2020 Mar 10;18(1):44
pubmed: 32151252
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Diabetes Care. 2020 Jul;43(7):1378-1381
pubmed: 32409505
Circulation. 2007 Nov 6;116(19):2119-26
pubmed: 17967769
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
Int J Epidemiol. 2019 Apr 1;48(2):640-653
pubmed: 30561628
Cardiovasc Diabetol. 2019 Jul 11;18(1):89
pubmed: 31296225
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258
pubmed: 32652195
Cell Metab. 2013 Jan 8;17(1):20-33
pubmed: 23312281
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Cardiovasc Diabetol. 2020 Jun 11;19(1):76
pubmed: 32527257
Br J Gen Pract. 2011 May;61(586):e262-70
pubmed: 21619750
Diabetes Metab. 2020 May 21;:
pubmed: 32447102